Key Takeaways
- Energy business crushed quarterly EBITDA: EBITDA collapsed to ₹202 crores from ₹311 crores QoQ as MMA volumes fell 36% on a crash in gasoline-naphtha and gasoline-crude spreads, overwhelming healthy 22% YoY non-energy volume growth.
- FY28 EBITDA target set at ₹1,800–2,200 crores: Management calls this "very realistic in current market conditions," with ₹500–750 crores of the bridge coming from cost optimisation and volume/margin ramp-up of already-installed capacity.
- Chinese overcapacity is the structural headwind: China built 5x–6x global demand in some PDA chain molecules and is dumping product globally because domestic demand never materialised; pricing may have bottomed but recovery timelines vary sharply by chain.
- MMA is both the problem and the hedge: The same product that drove Q2's collapse derisked overall EBITDA when the rest of the chemical market was down; management is betting on geography and customer diversification to reduce volatility over two to three years.
- What to watch next quarter: Whether MMA volumes recover as promised in Q3, the pace of cost-optimisation savings accrual, and any concrete progress on strategic partnerships for higher-end PDA molecules.
The Quarter: What Happened
- Energy segment drove the miss: MMA volumes dropped 36% QoQ because the gasoline-crude crack and gasoline-naphtha spread both compressed sharply, destroying the economics of octane boosting; higher global refinery runs and seasonal patterns added to the pressure.
- Non-energy volumes grew 22% YoY: Dyes, pigments, polymer additives and pharma all showed healthy volume growth; agrochemicals remained soft but with what management called green shoots of recovery.
- Pricing pressure is broad-based: Genuine margin erosion across the portfolio from the combination of Chinese overcapacity and demand that fell short of expectations in many product categories; management believes pricing may have reached a bottom, with limited ability to fall further from most players' perspective.
- Freight costs spiked then eased: Higher freight costs from Middle East tensions hit earlier in Q2 but started easing in recent weeks.
- Capacity utilisation sits at 50–60% on new assets: Recently expanded capacities in NT, Ethylation and MMA are at low utilisation, creating operating leverage for future growth without incremental capex.
Suyog Kotecha: "We accept the fact that as the MMA got launched, I think the volatility increased in terms of performance. At the same time, I want all of us to also look at the fact that because of that 'development', we were actually able to derisk our overall EBITDA performance quite significantly when the rest of the chemical market was down."
The FY28 Bridge: How Management Plans to Get There
- Three buckets of EBITDA drivers: Cost optimisation (₹150–200 crore potential), volume and margin ramp-up of already-expanded capacity (₹350–550 crore upside), and strategic initiatives including new products and partnerships.
- Cost optimisation is already in execution: Back-pressure turbines installed in one zone with expansion planned; renewable power phase one commissioned and delivering savings, phase two approved at this Board Meeting; waste energy stream utilisation, ETP cost optimisation, and fixed cost reduction through debottlenecking all underway, with savings expected over the next six to nine months.
- Volume ramp-up is the larger lever: Acid, DCB and NCB chains where capacity was expanded earlier are already ramping and could hit 85–90% utilisation in one to one-and-a-half years; Ethylation and NT volumes just commissioning and will ramp over two years; MMA ramp-up is a longer-term story with significant capacity available and the ability to expand beyond 200KT with negligible capex.
- Capex-led growth is back-ended: Zone 4 pilot plant recently commissioned; the Multipurpose Plant likely commissioned by mid-next year with commercialisation gradually over the following 18 months; the UPL JV is expected to ramp in volume and margin only in the latter part of FY28.
- Assumptions are deliberately conservative: Only very marginal pricing improvement is baked in, not fully normalised margins in many chains; MMA is not assumed to reach full potential; Zone 4 gets only one to one-and-a-half years of ramp-up in the FY28 window.
Suyog Kotecha: "The numbers that we are currently forecasting as a potential guidance ₹1,800 crores to ₹2,200 crores are very realistic in current market conditions."
MMA: The Volatile Growth Engine
- The product and the market: MMA improves the octane performance of gasoline blends; demand is driven by the premium available for that improvement, which is the naphtha-gasoline delta and the gasoline-crude crack, not the absolute crude price. Both spreads compressed significantly in Q2.
- Aarti is the largest player by far: Management asserts the company will remain the largest player for the visible future given its technology, cost position and customer servicing capability; it has scaled up from nowhere in a relatively short timeframe and continues to take market share despite competing octane boosters like MTBE and ethanol.
- Customer diversification is the derisking strategy: Initial success in the US market has been achieved; the plan is to replicate that in Europe and Singapore, and to scale direct sales to refineries from two or three today to 15–20 over a two-to-three-year timeframe. Bulk shipment capability has been established, with one shipment going in October.
- The sales cycle is long and margin-sensitive: Approaching a new customer, sending samples, running trials, establishing economics and negotiating typically takes four to eight months; when margins are good the process can compress, but when margins are under pressure it elongates.
- Q3 should look better: Management stated that October and Q3 numbers will look better than Q2 from a volume point of view, though it declined to call a bottom, saying that depends on how refinery cracks evolve over the next six to twelve months amid geopolitics, refinery runs and gasoline demand.
Suyog Kotecha: "Using the term bottoming out, I think is sort of stretching it, because ultimately it depends on how the refinery cracks both gasoline-naphtha delta as well as the gasoline-crude crack evolve over the course of next two, three sort of six, nine, twelve months kind of timeframe where there are multiple other aspects, right, from geopolitics to refinery runs to the demand for gasoline and the impact on that from several other factors."
The China Overcapacity Problem
- How it happened: China built capacity from a self-sufficiency perspective in 2015–2019; then COVID years (2021–2022) saw abnormal profitability that triggered massive expansion. All that capacity was commissioned recently, just as Chinese domestic demand collapsed, particularly in real estate, forcing product to be dumped globally.
- The scale in PDA is extreme: China has built 5x–6x of global demand in some PDA chain molecules and operates at price points where Aarti may choose not to participate; utilisation uptick depends on developing higher-end value-added PDA molecules in strategic partnerships with Western customers, but those conversations are early.
- Aarti claims cost competitiveness: Management says that at current price levels many Chinese players are bleeding with net negative P&Ls, while Aarti is able to run assets almost at full capacity where expansions happened earlier, remaining one of the best in conversion yield and energy norms in its value chains.
- Margin recovery timelines vary by chain: For the NCB chain with domestic and pharma exposure, margin pressure should start easing much earlier; for the PDA chain with export exposure and large Chinese capacity, the recovery timeframe could be significantly longer.
- Management declined to answer why Chinese players keep selling at a loss: When asked directly, the CEO said "It's difficult for me to answer" and redirected to a broader industry question.
Suyog Kotecha: "That abnormal profitability and with the base assumption that we will continue to grow at our historical rate is what led to Chinese to expand so massively... that domestic demand of China which was supposed to expect it to grow at historical growth rate actually never materialized... And that's what leads to margin pressure from a near term timeframe."
Long-Term Contracts: The Annuity Base
- Contract-two (20-year, polymer applications): Operating at full capacity and having its best year historically; EBITDA is protected per contract terms and not linked to volumes.
- Contract-three (10-year, specialty chemical intermediates): Product stabilisation and qualification took longer than expected; commercial orders and deliveries have now started, with ramp-up to peak levels expected in the FY27 timeframe.
- Contract-four (agrochem intermediate): Peak expected in the next 18 months as recently expanded capacity ramps up.
- Contract-five (four-year, niche oil and gas specialty chemical): Month-on-month volatility but robust potential over the four-year timeframe.
- Contract-six (20-year Nitric Acid sourcing): Major savings will kick in from the second half of FY26.
- Contract-one (10-year, cancelled June 2020): Precursor capacity has been successfully utilised over the last three to six months; downstream capacity is still being developed for new products.
Organisation, Capital Allocation & New Bets
- CEO transition complete: Suyog Kotecha onboarded as Executive Director and CEO in the company's 40th year; Rajendra Gogri moves to a facilitator role managing stakeholders, evaluating opportunities and passing investment decisions. The CXO structure (Chief Manufacturing Officer, Chief Scientific Officer, Chief Technology Officer, Chief CHRO) hired between 2017 and 2020 is described as well-established with "impeccable pedigree."
- Capex has peaked: FY25 capex is guided at ₹1,300–1,500 crores; FY26 around ₹1,000 crores; management says it will still pursue attractive growth opportunities if they arise, but hurdle rates are now more stringent given market conditions.
- Debt-to-EBITDA target: Currently around 3x–3.3x, aspiring to reach less than 2.5x in the next two to three years, with confidence based on the current capex programme and expected cash flows.
- Asset-light growth being explored: Management is looking at outsourcing and tolling models to serve customers using technical and R&D capabilities without investing its own assets.
- Early bets on sunrise sectors: Circularity and chemical recycling, electronic chemicals, and specialty chemistries in battery materials are in early development; battery materials could commercialise in three to five years via joint development with a few players; electronic chemicals are described as "early bets."
- Strategic partnerships targeted: Management hopes to conclude some partnerships in the next six to twelve months, with five-plus projects in active conversations.
Rajendra Gogri: "I think we are currently, I would say, we are in very challenging times as well as very exciting times. Challenging is in the sense that volumes are recovering, but the margins of the products are under pressure because in the last two years, post-COVID, in China, a lot of capacities have come up for most of the products, which is tending to keep margins under pressure."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 EBITDA | Broadly similar to last year, roughly ₹1,000–1,050 crores | FY25 full year |
| FY28 EBITDA | ₹1,800–2,200 crores | FY28 |
| FY25 capex | ₹1,300–1,500 crores | FY25 |
| FY26 capex | Around ₹1,000 crores | FY26 |
| Debt-to-EBITDA | Less than 2.5x (from current ~3x–3.3x) | Next two to three years |
| ROCE target | Greater than 15% | No specific date; stated as target |
| Cost optimisation savings | ₹150–200 crore EBITDA potential | Accruing over next six to nine months |
| Acid, DCB, NCB chain utilisation | Upwards of 85–90% | Next one to one-and-a-half years |
| Ethylation and NT volume ramp-up | Gradual ramp-up of newly commissioned capacity | Next two years |
| Contract-three ramp-up | Ramp to peak levels | FY27 timeframe |
| Contract-four peak | Peak volumes | Next 18 months |
| Contract-six Nitric Acid savings | Major savings kick in | Second half of FY26 |
| Zone 4 Multipurpose Plant commissioning | Plant commissioned | Middle of next year |
| Zone 4 commercialisation | Phase-wise commissioning begins accruing | Gradually over next 18 months |
| UPL JV ramp-up | Volume and margin ramp-up | Latter part of FY28 |
| MMA direct refinery customer scaling | Scale from 2–3 to 15–20 refineries | Two to three years |
| MMA Q3 recovery | October/Q3 volumes better than Q2 | Q3 FY25 |
| Strategic partnerships | Hope to conclude some | Next six to twelve months |
| Battery materials commercialisation | Joint development, potential commercialisation | Three to five years |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | Not stated as absolute figure; Energy segment contributed 32% of revenue, down from 41% in Q1 |
| EBITDA | ₹202 cr, down from ₹311 cr in Q1 FY25 |
| H1 FY25 EBITDA | ₹512 cr, up 18% YoY from ₹434 cr in H1 FY24 |
| H1 FY25 PAT | ₹189 cr, versus ₹160 cr in H1 FY24 |
| Exceptional income | ₹2.3 cr, from divestment of stake in a step-down subsidiary |
| Full-year FY25 EBITDA guidance | ₹1,000 cr to ₹1,050 cr, broadly similar to last year; previous guidance of ₹1,500 cr cut by 40% |
| FY28 EBITDA target | ₹1,800 cr to ₹2,200 cr, driven by volume growth, operating leverage, and cost optimisation |
| Non-energy volume growth | ~22% YoY, across dyes, pigments, polymer additives; agrochemicals remain soft |
| Energy business (MMA) volume change | 36% QoQ decline in Q2, from ~31 KT in Q1 to 20.5 KT |
| Aggregate entity-level volume growth | 15% YoY |
| MMA capacity | ~200 KTPA, expansion completed in Q2; can expand further with minor investment |
| Energy Additives segment revenue share (H1 FY25) | 37% of total revenue, 77% export, 23% domestic |
| Agrochem & Fertilisers revenue share | ~19% of total revenue, 40:60 export:domestic mix |
| Dyes, Pigments & Printing Inks revenue share | ~12% of total revenue, 72% domestic, 28% export |
| Pharmaceuticals revenue share | ~9% of total revenue, 99% domestic; growing at 8% to 9% per annum |
| Polymer & Additives revenue share | ~13% of total revenue, 85% exports, 15% domestic |
| Cost optimisation EBITDA potential | ₹150 cr to ₹200 cr, from steam, power, fixed cost, and yield improvements; savings expected over next 6 to 9 months |
| Volume and margin ramp-up EBITDA upside | ₹350 cr to ₹550 cr, from expanded capacities over next 2 to 3 years |
| Capex-led growth EBITDA contribution | ₹300 cr to ₹450 cr, from FY25 to FY28 timeframe |
| FY25 Capex | ₹1,300 cr to ₹1,500 cr, reduced from earlier estimate of ₹1,500 cr to ₹1,800 cr; ₹670 cr spent in H1 |
| FY26 Capex | ~₹1,000 cr, combination of maintenance and zone 4 |
| Renewable power target | >70% of external power purchase from renewable sources by end of 2026 |
| Debt-to-EBITDA | ~3x to 3.3x currently; management target less than 2.5x, to be achieved in next 2 to 3 years |
| ROCE target | >15% |
| MMA client development timeline | 4 to 8 months per new client in normal scenario |
| MMA refineries currently supplied | 2 to 3 refineries; potential to scale to 15 to 20 refineries over 2 to 3 years |
| Global MTBE market size | ~3.5 crore tons annually |
| Long-term contract (Contract-two, Polymer Additives) | Operating at highest historical throughput this year |
| Contract-three ramp-up timeline | Expected to reach peak levels by FY27 |
| Contract-four peak timeline | Expected within next 18 months |
| Contract-six (Nitric Acid sourcing) savings | Major savings to kick in from H2 FY26 |
| NT and Ethylation capacity expansion | Expanded from 10 KT to 25-30 KT, commissioning in progress |
| PDA chain capacity context | China capacity at 5x to 6x of global demand for some molecules |